16 Mar 2021 - 16:17
The Peninsula Online
Doha: Hamad Medical Corporation (HMC) is using Convalescent Plasma Therapy to treat COVID-19 patients in Qatar. Plasma from one recovered patient can be used to treat one to two infected patients.
HMC in a post encouraged recovered patients to donate plasma and explained how the donation can be made and how the therapy works.
“With the help of our clinical teams, you have recovered from COVID-19 infection. However, there are many other patients who are still suffering from this infection and you can help them to recover by donating your plasma. Plasma from one recovered patient can be used to treat one to two infected patients,” HMC said on their website.
Before COVID vaccine, convalescent plasma was used to treat patients. How is it being used today?
KABC
Share:
LOS ANGELES (KABC) Long before vaccines, the focus was on a handful of COVID-19 treatments that provided glimmers of hope. The first to emerge was convalescent plasma. It offered a way for survivors to help those still suffering.
Golden plasma, teeming with precious antibodies, was tilled from the donated blood of coronavirus survivors - like now-retired LAPD Cmdr. Cory Palka.
The 34-year police veteran donated at American Red Cross centers three times before his antibodies waned. Through donating blood, plasma and my organs.I think there s no greater testament to my faith and to my life of caring for others, he said.
Application Deadline: 31 July 2021
The Council of Scientific and Industrial Research (CSIR) of India and TWAS have established a number of fellowships for foreign scholars from developing countries who wish to pursue research toward a PhD in emerging areas of science and technology for which facilities are available in the laboratories and institutes of the CSIR.
CSIR and TWAS will keep about 20% of 2021 awards for COVID-19 related research topics.
These could be in the area of :
I. Digital and Molecular Surveillance;
II. Rapid and Economical Diagnostics;
III. Repurposing of Drugs, Vaccine and Convalescent Plasma Therapy;
IV. Hospital Assistive Devices and PPEs.
Three of the trials did not have study acronyms (only trial registration numbers) and ILBS-COVID-02 and PLACID did not have expansions in the original publications. ConCOVID indicates Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease; ConPlas-19, Convalescent Plasma Therapy vs SOC for the Treatment of COVID-19 in Hospitalized Patients; NA, not available; PICP19, Passive Immunization With Convalescent Plasma in Severe COVID-19 Disease; PlasmAr, Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia; RECOVERY, Randomized Evaluation of COVID-19 Therapy.
aThere was no detailed information reported regarding (1) the randomization process or (2) the concealment of randomized assignment.
bThere was no detailed information reported regarding (1) the randomization process, (2) the concealment of randomized assignment, (3) the flow of patients through the trial, and (4) possible deviations from the intended interventions due to the open-label setti